Antibody therapeutics companies develop engineered antibodies that target specific molecules involved in disease. These medicines are used across oncology, autoimmune disease, inflammatory conditions, infectious disease and other areas of clinical development.
This category includes companies working on:
Browse 75 UK antibody therapeutics companies below.
Clinical-stage rare disease biotech acquiring deprioritised pharma assets
Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Founded in 2015, its business model centres on acquiring clinical-stage programmes deprioritised by large pharmaceutical companies and advancing them through further development. Lead programmes include…
Engineered biologics with conditional activation for precision cancer immunotherapy
Switch Biologics is a UK biotechnology company developing engineered protein biologics for cancer immunotherapy. The company applies directed evolution and protein engineering to build conditionally activated therapeutics that respond to two simultaneous molecular signals, a design intended to concentrate activity…
ML-driven antibody discovery platform for solid tumour therapeutics
LabGenius Therapeutics is a company developing next-generation therapeutic antibodies using its closed-loop machine learning platform. The platform integrates AI, robotic automation and high-throughput experimentation to co-optimise multispecific antibodies across potency, selectivity and manufacturability…
AI-designed antibody biologics adapting human therapeutics for companion animals
Antigenesis Biologics is a biotechnology company developing targeted biological treatments for companion animals, applying expertise in human antibody therapeutics to address a gap between human and veterinary healthcare innovation. The company uses AI and computational design approaches to develop antibody-based…
AstraZeneca's rare disease arm targeting the complement cascade
Alexion, AstraZeneca Rare Disease is the rare disease group within AstraZeneca, formed following the 2021 acquisition of Alexion Pharmaceuticals. With nearly 30 years of rare disease heritage, the division focuses on novel molecules targeting the complement cascade across haematology, nephrology, neurology, metabolic…
Antibody therapies depleting pathogenic T cells for autoimmune disease cure
Re-Aim Therapeutics is a biotechnology company developing antibody-based therapies designed to achieve functional cures for T cell-mediated autoimmune diseases. The company's approach selectively depletes pathogenic T cell subsets that drive chronic inflammation, using precise targeting of disease-relevant membrane…
Antibody therapy to deplete amyloid deposits in ATTR cardiomyopathy
Immutrin is a biotechnology company developing an engineered antibody therapeutic designed to actively remove amyloid deposits from tissues in patients with amyloidosis. Its lead asset targets ATTR cardiomyopathy, a progressive and often fatal cardiac disease caused by transthyretin amyloid accumulation, for which no…
Specialty biopharma covering oncology, neurology, and fertility
Merck Serono Limited is the UK commercial subsidiary of Merck KGaA's Healthcare division, a German science and technology company founded in 1668. The UK operation markets prescription medicines across oncology, neurology, immunology, endocrinology, and fertility. Key products include Erbitux for colorectal and…
Clinical-stage oncology biopharma developing the bispecific antibody ivonescimab
Summit Therapeutics is a clinical-stage oncology company with UK research operations originating from VASTox, a University of Oxford spin-out. The company's lead candidate, ivonescimab, is a bispecific antibody targeting PD-1 and VEGF, in-licensed from Akeso and now in multiple global Phase III trials across non-small…
Immuno-oncology target discovery and antibody therapeutics developer
4C Biomed is a biotechnology company developing immuno-oncology therapies and target discovery platforms based on patient-derived tumour and immune cell systems. The company uses integrated screening technologies and clinical data to identify novel immune targets and develop antibody therapeutics designed to enhance…
Bispecific antibody-drug conjugates for hard-to-treat solid tumours
Valink Therapeutics is a biotechnology company developing next-generation bispecific antibody-drug conjugates and multispecific antibody therapeutics for oncology. Its proprietary discovery platform enables modular assembly of complex antibody formats combining multispecificity, multivalency, and drug conjugation,…
Global pharma company in oncology, immunology, and neuroscience
Johnson & Johnson is a multinational pharmaceutical company with UK operations spanning commercial, medical affairs, and innovation activities. Its Innovative Medicine division covers oncology, immunology, neuroscience, and infectious disease. The company operates an EMEA Innovation Centre in London focused on…
CSF-1R antibody therapy for tenosynovial giant cell tumour
SynOx Therapeutics is a late-stage biopharmaceutical company developing emactuzumab, a humanised monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumour and other macrophage-driven conditions. Emactuzumab was licensed from Roche and inhibits the CSF-1 receptor to deplete…
Global pharmaceutical company developing medicines across major disease areas
AstraZeneca is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of prescription medicines. Its pipeline and product portfolio span oncology, cardiovascular and metabolic disease, respiratory and immunology, rare diseases, and vaccines. The company…
Cancer immunotherapies targeting novel antigens from the dark genome
Enara Bio is a clinical-stage biopharmaceutical company developing cancer immunotherapies directed against Dark Antigens, a class of cancer-specific targets derived from previously uncharted genomic dark matter. Its platform integrates bioinformatics, immunopeptidomics, and immunology to discover and validate novel…
Data-driven cis-bispecific antibody-drug conjugates for solid tumour cancers
Promatix Biosciences is an oncology drug discovery company developing next-generation bispecific antibody-drug conjugates through data-driven target pairing. Using a proteomics database and computational algorithms, the company identifies antigen combinations enabling selective tumour targeting, aiming to reduce…
Global biopharma focused on severe neurological and immunological diseases
UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological diseases. The UK operation is one of UCB's three global R&D hubs, with capabilities spanning antibody discovery, small molecule development,…
Immuno-oncology therapies targeting the nfP2X7 cancer receptor
Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform. The nfP2X7 receptor is a non-functional form of P2X7 expressed on cancer cells across a broad range of tumour types, enabling targeted therapeutic approaches. The pipeline…
ADC pipeline targeting mutant stem cells in blood cancers
Alethio Therapeutics Limited is a preclinical-stage biotechnology company developing antibody-drug conjugates for myeloproliferative neoplasms, a group of chronic blood cancers. Its pipeline targets the mutant stem and progenitor cells that drive disease progression and fibrosis, with the aim of modifying rather than…
Off-the-shelf cancer immunotherapies targeting solid tumours
Scancell is a clinical-stage biotech developing active immunotherapies and antibody-based therapeutics for cancer. Its pipeline spans DNA cancer vaccines, peptide immunotherapies and tumour-specific monoclonal antibodies targeting glycans expressed on cancer cells. Lead programmes iSCIB1+ and Modi-1 are in Phase 2…